Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Multi-center, Open, Comparative, Paralleled, Roll-over Study to Assess the Safety and Antiviral Activity of LB80380 Tablet Compared to Entecavir 0.5 mg After Additional 48 Weeks of Treatment in Chronic Hepatitis B Patients Who Have Completed LG-BVCL007 Study

NCT01242787 is registered in ClinicalTrials.gov with LG Life Sciences as lead sponsor.

NCT NCT01242787
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01242787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Multi-center, Open, Comparative, Paralleled, Roll-over Study to Assess the Safety and Antiviral Activity of LB80380 Tablet Compared to Entecavir 0.5 mg After Additional 48 Weeks of Treatment in Chronic Hepatitis B Patients Who Have Completed LG-BVCL007 Study
Lead sponsor
LG Life Sciences
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2010
Completion date
September 30, 2012
Enrollment
115 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b